Imdur (Isosorbide Mononitrate)

Isosorbide mononitrate is converted in the body to nitric oxide, which relaxes vascular smooth muscle. This vasodilation decreases preload and afterload, reducing myocardial oxygen consumption and alleviating anginal symptoms.

The specific dose of Imdur is determined by the prescribing clinician based on the patient’s condition, response, and tolerability. Dosage adjustments are made according to individual therapeutic needs and safety considerations.

Safety data for isosorbide mononitrate in pregnancy and lactation are limited. The medication should only be used if the potential benefit justifies any potential risk to the fetus or infant, and this decision must be made by a qualified healthcare professional.

To request Imdur, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Imdur belongs to the nitrate class, offering long‑acting vasodilation. Compared with short‑acting nitrates, it provides more stable plasma levels and fewer dosing peaks, which can improve adherence. It differs from beta‑blockers or calcium‑channel blockers that act through distinct mechanisms such as heart‑rate reduction or calcium antagonism.

Imdur should be stored at room temperature, below 25 °C, in its original container. Protect the tablets from moisture and direct sunlight to maintain stability and potency throughout its shelf life.

Imdur is taken orally, usually with a glass of water. It can be taken with or without food, but patients should follow the prescribing clinician’s instructions regarding timing and any specific administration guidelines.

The most serious risks include severe hypotension, which can lead to syncope or shock, and rare cases of methemoglobinemia. Patients should be educated to seek immediate medical attention if they experience fainting, persistent dizziness, or signs of low oxygen in the blood.

Imdur is contraindicated in patients with known hypersensitivity to isosorbide mononitrate or other nitrates, those who have taken phosphodiesterase‑5 inhibitors within the past 24‑48 hours, and individuals with severe hypotension or uncompensated heart failure unless specifically directed by a physician.